• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by QuidelOrtho Corporation

    5/27/25 4:31:27 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email
    8-K
    QuidelOrtho Corp false 0001906324 0001906324 2025-05-20 2025-05-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 20, 2025

     

     

    QUIDELORTHO CORPORATION

    (Exact name of Registrant as specified in its Charter)

     

     

     

    Delaware   001-41409   87-4496285

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    9975 Summers Ridge Road, San Diego, California 92121

    (Address of principal executive offices, including zip code)

    (858) 552-1100

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 Par Value   QDEL   The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    On May 20, 2025, QuidelOrtho Corporation (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”).

     

    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    At the Annual Meeting, the Company’s stockholders approved the adoption of the Company’s Second Amended and Restated 2018 Equity Incentive Plan (the “Second A&R 2018 Plan”) to amend and restate the Company’s Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”) to (1) increase the number of shares of the Company’s common stock authorized for issuance under the 2018 Plan by 6,200,000 shares; (2) extend the term of the 2018 Plan to May 20, 2035; and (3) make related administrative changes.

    For additional information regarding the Second A&R 2018 Plan, please refer to the heading “Summary of the Second Amended and Restated 2018 Equity Incentive Plan” contained in Proposal 2 of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2025 (the “Proxy Statement”).

    The foregoing description and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Second A&R 2018 Plan, which is filed hereto as Exhibit 10.1.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    The following are the final voting results on proposals considered and voted upon at the Annual Meeting, all of which are described in the Proxy Statement.

    Proposal No. 1

    The Company’s stockholders elected the eleven director nominees to the Company’s Board of Directors by the votes set forth in the table below:

     

    Name    Votes For      Votes Withheld      Broker Non-Votes  

    Brian J. Blaser

         59,138,889        321,909        3,395,934  

    Kenneth F. Buechler, Ph.D.

         56,977,744        2,483,054        3,395,934  

    John R. Chiminski

         59,197,660        263,138        3,395,934  

    Evelyn S. Dilsaver

         58,981,998        478,800        3,395,934  

    R. Scott Huennekens

         57,592,571        1,868,227        3,395,934  

    Edward L. Michael

         58,956,730        504,068        3,395,934  

    Mary Lake Polan, M.D., Ph.D., M.P.H.

         58,499,916        960,882        3,395,934  

    Ann D. Rhoads

         58,295,029        1,165,769        3,395,934  

    Matthew W. Strobeck, Ph.D.

         59,181,025        279,773        3,395,934  

    Kenneth J. Widder, M.D.

         58,150,438        1,310,360        3,395,934  

    Joseph D. Wilkins Jr.

         58,659,151        801,647        3,395,934  


    Proposal No. 2

    The Company’s stockholders approved the adoption of the Second A&R 2018 Plan by the votes set forth in the table below:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    56,197,594   3,246,510   16,694   3,395,934

    Proposal No. 3

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the votes set forth in the table below:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    53,564,697   5,878,744   17,357   3,395,934

    Proposal No. 4

    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s 2025 fiscal year by the votes set forth in the table below:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    62,737,831   67,035   51,866   0

     

    Item 9.01

    Financial Statements and Exhibits.

     

      (d)

    Exhibits.

    The following exhibit is filed with this Form 8-K:

     

    Exhibit
    Number

      

    Description of Exhibit

    10.1    QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan.
    104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: May 27, 2025

     

    QUIDELORTHO CORPORATION
    By:  

    /s/ Michelle A. Hodges

    Name:   Michelle A. Hodges
    Its:   Secretary
    Get the next $QDEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Rhoads Ann D

      4/A - QuidelOrtho Corp (0001906324) (Issuer)

      6/3/25 4:08:16 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Busky Joseph M. was granted 5,392 shares and covered exercise/tax liability with 2,466 shares, increasing direct ownership by 17% to 19,943 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      6/3/25 4:03:54 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Polan Mary Lake Ph D

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      6/2/25 4:26:56 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care